OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pfizer’s Humira Biosimilar Displays Positive Top Line Results
PF-06410293 met primary endpoints during clinical trials and demonstrated similar efficacy to its reference product.
Results from a REFLECTIONS B538-02 trial with Pfizer’s investigational Humira (adalimumab) biosimilar, PF-06410293, showed that the drug met its primary endpoint, and demonstrated similar efficacy to its reference product. PF-06410293 is being evaluated in combination with methotrexate as a treatment for moderate to severe rheumatoid arthritis, the company said in a Jan. 5, 2017 announcement.
PF-06410293 is Pfizer’s second proposed inflammation biosimilar. The company’s pipeline consists of eight biosimilar molecules in mid- to late-stage development. Pfizer also said it has several other biosimilar molecules currently in early-stage development. Pfizer will likely face competition in the Humira biosimilar market. FDA approved the first biosimilar to Humira, Amjevita (adalimumab-atto), marketed by Amgen in the United States, in late September 2016.
Source: Pfizer
Related Content:
